These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 37720221)
1. The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies. Xu J; Shi Q; Wang B; Ji T; Guo W; Ren T; Tang X Front Immunol; 2023; 14():1257254. PubMed ID: 37720221 [TBL] [Abstract][Full Text] [Related]
2. Complex immune microenvironment of chordoma: a road map for future treatment. Niu HQ; Zheng BY; Zou MX; Zheng BW J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908855 [TBL] [Abstract][Full Text] [Related]
3. Immune microenvironment and immunotherapy for chordoma. Chen Y; Zhang H Front Oncol; 2024; 14():1374249. PubMed ID: 38983929 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy as a Potential Treatment for Chordoma: a Review. Patel SS; Schwab JH Curr Oncol Rep; 2016 Sep; 18(9):55. PubMed ID: 27475804 [TBL] [Abstract][Full Text] [Related]
5. The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol. Banu MA; Raza SM; Amini M; Seaman S; Rubino F; Snyder R; Patel S; DeMonte F; Conley AP Neurosurg Focus; 2024 May; 56(5):E15. PubMed ID: 38691867 [TBL] [Abstract][Full Text] [Related]
6. Multimodal profiling of chordoma immunity reveals distinct immune contextures. van Oost S; Meijer DM; Ijsselsteijn ME; Roelands JP; van den Akker BEMW; van der Breggen R; Briaire-de Bruijn IH; van der Ploeg M; Wijers-Koster PM; Polak SB; Peul WC; van der Wal RJP; de Miranda NFCC; Bovee JVMG J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272563 [TBL] [Abstract][Full Text] [Related]
7. Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors. Shinojima N; Ozono K; Yamamoto H; Abe S; Sasaki R; Tomita Y; Kai A; Mori R; Yamamoto T; Uekawa K; Matsui H; Nosaka K; Matsuzaki H; Komohara Y; Mikami Y; Mukasa A Brain Tumor Pathol; 2023 Jul; 40(3):185-190. PubMed ID: 37086325 [TBL] [Abstract][Full Text] [Related]
9. Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression. Xu J; Shi Q; Lou J; Wang B; Wang W; Niu J; Guo L; Chen C; Yu Y; Huang Y; Guo W; Lan J; Zhu Y; Ren T; Tang X J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37185233 [TBL] [Abstract][Full Text] [Related]
10. Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies. Lopez DC; Robbins YL; Kowalczyk JT; Lassoued W; Gulley JL; Miettinen MM; Gallia GL; Allen CT; Hodge JW; London NR Front Oncol; 2022; 12():1012058. PubMed ID: 36338744 [TBL] [Abstract][Full Text] [Related]
11. The role and participation of immune cells in the endometrial tumor microenvironment. Dey DK; Krause D; Rai R; Choudhary S; Dockery LE; Chandra V Pharmacol Ther; 2023 Nov; 251():108526. PubMed ID: 37690483 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors. Medikonda R; Pant A; Lim M Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of Pyroptosis-Related Genes and Tumor Microenvironment Infiltration Characterization in Breast Cancer. Wu J; Zhu Y; Luo M; Li L Front Immunol; 2021; 12():748221. PubMed ID: 34659246 [TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment and immunotherapy of oral cancer. Liu C; Wang M; Zhang H; Li C; Zhang T; Liu H; Zhu S; Chen J Eur J Med Res; 2022 Oct; 27(1):198. PubMed ID: 36209263 [TBL] [Abstract][Full Text] [Related]
15. Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells. Hoke ATK; Padget MR; Fabian KP; Nandal A; Gallia GL; Bilusic M; Soon-Shiong P; Hodge JW; London NR Cancer Res Commun; 2021 Dec; 1(3):127-139. PubMed ID: 35765577 [TBL] [Abstract][Full Text] [Related]
16. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option. Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G Front Immunol; 2022; 13():961796. PubMed ID: 35911673 [TBL] [Abstract][Full Text] [Related]
17. Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy. Gounder MM; Zhu G; Roshal L; Lis E; Daigle SR; Blakemore SJ; Michaud NR; Hameed M; Hollmann TJ Clin Cancer Res; 2019 Apr; 25(7):2064-2071. PubMed ID: 30642912 [TBL] [Abstract][Full Text] [Related]
18. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. Fujii R; Schlom J; Hodge JW J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113 [TBL] [Abstract][Full Text] [Related]
19. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549 [TBL] [Abstract][Full Text] [Related]
20. Research progress on the impact of intratumoral microbiota on the immune microenvironment of malignant tumors and its role in immunotherapy. Xu J; Cheng M; Liu J; Cui M; Yin B; Liang J Front Immunol; 2024; 15():1389446. PubMed ID: 39034996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]